Chiasma was acquired by Amryt Pharma on August 5, 2021. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a growing commercial business and a significant development pipeline.
Please Follow us at https://www.linkedin.com/company/amryt-pharma